Enabling precision medicine in cancer through precise cytopathology diagnostic
Huge backlog in pathology clinics
The pathology workforce crisis has been going on for numerous years. COVID-19 has just worsened the situation by dramatically increasing the workload.
“The field of Clinical Immunohistochemistry (IHC) is beset with a high error rate, an order of magnitude higher than in other types of clinical laboratory testing”
STEVEN A BOGEN, 2019
“PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation”
Cleo keppens et al., 2020
A novel immunolabeling
Our proposed immunolabeling, allows to bring quantitativity and multiplexing in cytopathology for a more accurate diagnostic. It is also compatible with standard H&E staining and allows for dual mode imaging in a simple switch.
Among the numerous advantages of using functionalized plasmonic nanoparticles as immunolabeling, the quantitativity of the staining is the key to achieving objective analysis of the samples.
Thanks to the unique optical properties of the plasmonic nanoparticles used as immunolabeling, we can have up to 4 markers in the same sample.
Compared to immunofluorescence, the immunoplasmonic labeling does not suffer from photo-bleaching, and allows for multiple examinations of the same sample.
A versatile diagnostic platform
Our research-grade diagnostic platform with 3D scanning and multiplexed detection capabilities has been developped to support biointeraction and bioimaging research.